Amylyx Pharmaceuticals, Inc. $AMLX Shares Acquired by Stempoint Capital LP

Stempoint Capital LP raised its holdings in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) by 18.5% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 669,685 shares of the company’s stock after purchasing an additional 104,545 shares during the quarter. Amylyx Pharmaceuticals accounts for 1.8% of Stempoint Capital LP’s portfolio, making the stock its 17th largest position. Stempoint Capital LP’s holdings in Amylyx Pharmaceuticals were worth $9,309,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Landscape Capital Management L.L.C. grew its position in shares of Amylyx Pharmaceuticals by 17.5% during the fourth quarter. Landscape Capital Management L.L.C. now owns 12,226 shares of the company’s stock worth $148,000 after buying an additional 1,825 shares in the last quarter. KBC Group NV acquired a new stake in Amylyx Pharmaceuticals in the first quarter valued at $26,000. Mirae Asset Global Investments Co. Ltd. boosted its stake in Amylyx Pharmaceuticals by 54.8% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,337 shares of the company’s stock valued at $64,000 after acquiring an additional 1,890 shares during the last quarter. Meeder Asset Management Inc. bought a new position in Amylyx Pharmaceuticals during the 4th quarter valued at $25,000. Finally, China Universal Asset Management Co. Ltd. grew its holdings in Amylyx Pharmaceuticals by 14.5% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 17,895 shares of the company’s stock worth $216,000 after acquiring an additional 2,265 shares in the last quarter. 95.84% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, insider Gina Mazzariello sold 15,000 shares of the company’s stock in a transaction that occurred on Thursday, July 9th. The stock was sold at an average price of $18.32, for a total transaction of $274,800.00. Following the completion of the transaction, the insider directly owned 194,090 shares of the company’s stock, valued at approximately $3,555,728.80. This represents a 7.17% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 10.90% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

AMLX has been the topic of a number of recent analyst reports. Wall Street Zen lowered shares of Amylyx Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of Amylyx Pharmaceuticals in a report on Friday, May 8th. Guggenheim upped their price objective on Amylyx Pharmaceuticals from $30.00 to $40.00 and gave the company a “buy” rating in a research note on Thursday, June 25th. Mizuho increased their target price on Amylyx Pharmaceuticals from $21.00 to $24.00 and gave the stock an “outperform” rating in a report on Monday, July 20th. Finally, HC Wainwright reiterated a “buy” rating and issued a $34.00 target price on shares of Amylyx Pharmaceuticals in a research report on Monday, June 8th. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, Amylyx Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $24.62.

Amylyx Pharmaceuticals Stock Performance

Amylyx Pharmaceuticals stock opened at $19.73 on Thursday. Amylyx Pharmaceuticals, Inc. has a 1 year low of $7.48 and a 1 year high of $20.21. The firm’s 50-day moving average is $16.27 and its 200-day moving average is $15.35. The company has a market cap of $2.19 billion, a P/E ratio of -13.15 and a beta of -0.20.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.03). As a group, sell-side analysts predict that Amylyx Pharmaceuticals, Inc. will post -1.4 earnings per share for the current year.

Amylyx Pharmaceuticals Company Profile

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx’s research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.

The company’s lead product, AMX0035, is marketed under the trade name Relyvrio following U.S.